High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - A phase II study

Bone Marrow Transplantation

Volumn 25, Issue 1, 2000, Pages 19-24

  Toh, H C ^a,b   McAfee, S L ^a   Sackstein, R ^a   Multani, P ^a   Cox, B F ^a   Garcia Carbonero, R ^b   Colby, C ^a   Spitzer, T R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adoptive immunotherapy; Graft versus tumor effect; High dose chemotherapy and stem cell transplantation; Interleukin 2; Metastatic breast cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; INTERLEUKIN 2; LORAZEPAM; MESNA; ONDANSETRON; PETHIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; BLADDER DISEASE; BREAST CARCINOMA; BREAST METASTASIS; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN CELL; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RIGOR; SKIN TOXICITY; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0033967184     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702091     Document Type: Article

References (22)

1. Guillaume T, Rubenstein DB, Symann M. Immune reconstitution and immunotherapy after hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1490.
2. Charak BS, Malloy B, Agah R et al. Interaction of various cytokines with interkeukin-2 in the generation of killer cells from human bone marrow: application in the purging of leukemia. Leukemia Res 1991; 9: 801-810.
3. Charak BS, Brynes RK, Chogyoji M et al. Graft vesus leukemia effect of interleukin-2 activated bone marrow: correlation with eradication of residual disease. Transplantation 1993; 56: 31-37.
4. Meehan KR, Verma UN, Cahill R et al. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. Bone Marrow Transplant 1997; 20: 643-651.
5. Charak BS, Brynes RK, Katsuda S et al. Induction of graft versus leukemia effect in bone marrow transplantation: dosage and time schedule dependency of interleukin-2 therapy. Cancer Res 1991; 51: 2015-2020.
6. Charak BS, Verma UN, Mazumder A. Immunomodulation in autologous bone marrow transplantation: experimental approaches. In: Spitzer T, Mazumder A (eds). Immunotherapy and Bone Marrow Transplantation. Futura: Armonk, NY, 1995, pp 35-58.
7. Agah R, Malloy B, Kerner M et al. Generation and characterization of IL-2 activated bone marrow cells as potent graft versus tumor effectors in transplantation. J Immunol 1989; 143: 3093-3099.
8. Mechan KR, Verma UN, Rajagopal C et al. Stem cell transplantation with chemoradiotherapy mycloablution and interleukin-2. J Infus Chemother 1996; 6: 28-32.
9. Lotze MT, Chang AE, Seipp CA et al. High dose recombinant IL-2 in the treatment of patients with disseminated cancer. JAMA 1986; 256: 3117-3124.
10. Spitzer TR, Cirenza E, McAfee S et al. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 537-542.
11. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
12. Peto R, Peto J. Asymmetrically efficient rank invariant test procedures. J R Stat Soc A 1972; 35: 185-206.
13. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
14. Hortobagyi GN. Treatment of breast cancer. New Engl J Med 1998; 339: 974-984.
15. Rahman ZU, Frye DK, Smith TL et al. Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999; 85: 104-111.
16. Robinson N, Benyunes MC, Thompson JA et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy - a phase I/II study. Bone Marrow Transplant 1997; 19: 435-442.
17. Miller JS, Tessmer-Tuck J, Pierson BA et al. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer activity. Biol Blood Marrow Transplant 1997; 3: 34-44.
18. Soiffer RJ, Murray C, Shapiro C et al. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res 1996; 2: 493-499.
19. Areman EM, Mazumder A, Kotula PL et al. Hematopoietic potential of IL-2 cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant 1999; 23: 27-33.
20. Kopp WC, Holmlund JT. Cytokines and immunological monitoring. In Pinedo HM, Longo DL, Chabner BA (eds). Cancer Chemotherapy and Biological Response Modifiers Annual 16. Elsevier Science BV: Amsterdam, 1996, pp 189-238.
21. Salazar R, Sola C, Maroto P et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27-33.
22. Hudis CA, Munster PN. High-dose therapy for breast cancer. Semin Oncol 1999; 26: 35-47.